New Presentations Sample Clauses

New Presentations. The Conversion Charge for any New ----------------- Presentations shall be calculated as follows: [*] where (A) is the average per unit (e.g., tablet) Conversion Charge for those presentations of such Secondary/Steriles Product having the same dosage size as the New Presentation; (B) is the unit size of the New Presentation; [*] where (W) is the average per dosage unit (e.g., mg) Conversion Charge for those presentations of such Secondary/Steriles Product having the same package size as the New Presentation; (X) is the dosage size (in units) of the New Presentation; [*] = CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. [*] The Conversion Charge for each New Presentation shall be recalculated following the [*] the New Presentation is supplied under this Agreement (or until that New Presentation is no longer supplied, whichever first occurs), [*] by Supplier with respect to that New Presentation and the actual unit volumes of that New Presentation with Delivery Dates during the period. Incremental costs used in the recalculation shall include only the types of costs included in the initial calculation, and only increases or decreases therein shall be reflected in the recalculation. If the recalculated Conversion Charge exceeds the Conversion Charge calculated prior to the commencement of supply of any such New Presentation, GWI shall promptly pay to Supplier an amount equal to the excess times the number of units of that New Presentation with Delivery Dates in such period. If the recalculated Conversion Charge is less than the Conversion Charge calculated prior to the commencement of supply of any such New Presentation, Supplier shall credit to GWI an amount equal to the difference times the number of units of such New Presentation with Delivery Dates in such period on Supplier's next invoices for Products until fully recovered. The amount of any credits not applied against invoices to GWI as of the Termination Date shall be paid by Supplier to GWI within [*] the Termination Date.
Sample 1
AutoNDA by SimpleDocs
New Presentations. (a) During the Term, each Party (the “Developing Party”) shall notify the other Party of each New Presentation for which it Controls the rights necessary for Commercialization in the other Party’s portion of the Territory and shall provide such factual information relating to the New Presentation as is likely to be material to the other Party’s decision whether to Develop and Commercialize the New Presentation in accordance with this Agreement, including, at least, the items listed on Exhibit K. Each New Presentation notice shall describe the New Presentation with a level of detail that is comparable to the level of detail set forth in Exhibit G with respect to the Initial Licensed Products. In addition to the information set forth in Exhibit K, if the [ * ] Confidential Treatment Requested Developing Party considers the New Presentation to be a Combination Product, the Developing Party will inform the other Party of the applicable allocation formula set forth in Exhibit C proposed to be applied in calculating the Net Sales of such New Presentation and the invoice price(s), if known, or the [ * ], proposed to be applied in performing such calculation. If the Developing Party proposes to apply [ * ], rather than invoice prices, in the calculation of Net Sales pursuant to Exhibit C for such New Presentation and if the other Party disagrees with the [ * ] proposed by the Developing Party, the matter shall be resolved [ * ]. If the Developing Party, in providing information pertaining to a New Presentation, does or does not characterize the New Presentation as a Combination Product and if the other Party disagrees, such matter (in addition to a determination of [ * ], if applicable) shall be resolved [ * ]. The determination [ * ] and shall apply whether such New Presentation becomes a Collaboration Product or a Declined Product; provided that if the allocation of Net Sales of a Combination Product is based on [ * ] and invoice prices become available, the invoice prices shall be used to allocate Net Sales in accordance with Exhibit C starting with the next calendar quarter.
Sample 1
New Presentations. From time to time, GSK may request Draxis to manufacture any of the Products in any package size or dosage size or for shipment into a country not set forth on the applicable Schedule 2.1 (each, a “New Presentation”). Subject to compliance with the provisions of Section 4.3 and Section 3.11(c) of this Agreement, Draxis shall manufacture New Presentations and the Parties shall negotiate in good faith to establish a timeline for commencing manufacture of any New Presentations at the Facility and a price for the New Presentation.
Sample 1

Related to New Presentations

  • Publications and Presentations The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall [********]. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) that relate to the Research Program [********] at least [********] prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [********] period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [********] from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it reasonably believes may be patentable. Further, AstraZeneca shall [********]. Once an abstract, manuscript or presentation has been reviewed and, in the case of any abstract, manuscript or presentation that relates to the Research Program, approved by a Party [********], the same abstract, manuscript or presentation does not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary standards. All such abstracts, manuscripts and presentations by or on behalf of Targacept shall [********]. Notwithstanding anything in this Section 7.3 to the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith and (b) permit AstraZeneca to review and comment on any such publication.

  • Representations and Compliance The representations of the Company contained in this Agreement were accurate as of the date of this Agreement and are accurate as of the Closing Date, in all respects (in the case of any representation containing any materiality qualification) or in all material respects (in the case of any representation without any materiality qualification), except for representations and warranties made as of a specific date, which shall be accurate as of such date. The Company shall in all material respects have performed each obligation and agreement and complied with each covenant to be performed and complied with by it hereunder at or prior to the Closing Date.

  • Presentations In the event the Prime is afforded the opportunity to make presentations, whether orally or in writing, to potential customers concerning the Procurement, the content of such presentations may, at the Prime’s discretion, be made known to the Subcontractor, subject to any prohibitions or restrictions that may be imposed by the Government upon such disclosure. The Subcontractor agrees to support such presentations, as may be requested by the Prime, to the extent such presentations relate to the Subcontractor’s area of work as defined in Exhibit A.

  • Representations and Agreements (a) The Advisor represents to and agrees with the Company that:

  • Basic Representations Section 3(a) of the Agreement is hereby amended by the deletion of “and” at the end of Section 3(a)(iv); the substitution of a semicolon for the period at the end of Section 3(a)(v) and the addition of Sections 3(a)(vi), as follows:

  • Representations, etc Any representation, warranty or statement made or deemed made by any Credit Party herein or in any other Credit Document or in any certificate delivered to the Administrative Agent or any Lender pursuant hereto or thereto shall prove to be untrue in any material respect on the date as of which made or deemed made; or

  • Representations True Borrower represents and warrants to Silicon that all representations and warranties set forth in the Loan Agreement, as amended hereby, are true and correct.

  • Representations and Warranties of MML Advisers (a) MML Advisers represents and warrants to the Subadviser the following:

  • Representations True and Correct The representations and warranties of the Investor contained in this Agreement shall be true and correct in all material respects on and as of the Closing Date with the same force and effect as if made on as of the Closing Date.

  • Correctness of Representations The Company represents that the foregoing representations and warranties are true and correct as of the date hereof in all material respects, and, unless the Company otherwise notifies the Subscribers prior to the Closing Date, shall be true and correct in all material respects as of the Closing Date.

Time is Money Join Law Insider Premium to draft better contracts faster.